| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/26/2001 | CA2396908A1 Benzimidazole derivative |
| 07/26/2001 | CA2396697A1 Antisense modulation of glycogen synthase kinase 3 beta expression |
| 07/26/2001 | CA2396307A1 Cyclic peptides as potent and selective melanocortin-4 receptor antagonists |
| 07/26/2001 | CA2396066A1 Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone |
| 07/26/2001 | CA2395054A1 Human polynucleotides, polypeptides, and antibodies |
| 07/26/2001 | CA2394703A1 Amide compounds for inhibiting protein kinases |
| 07/26/2001 | CA2388885A1 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| 07/26/2001 | CA2365118A1 Inhibitor against human chymase activity |
| 07/26/2001 | CA2332214A1 Compositions and methods for treating osteoporosis and lowering cholesterol |
| 07/25/2001 | EP1118678A1 Method for diagnosing polymorphisms in the human PDH E1 beta gene |
| 07/25/2001 | EP1118663A1 Nucleic acids encoding chemotaxis inhibitory polypeptides |
| 07/25/2001 | EP1118660A1 Enzyme producing plasma protein fragment having effect of inhibiting cancer metastasis and plasma protein fragment fragmented by the enzyme |
| 07/25/2001 | EP1118615A1 Novel salts of pyridopyrazine compound and crystals thereof |
| 07/25/2001 | EP1118610A1 Benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them |
| 07/25/2001 | EP1118328A1 Insertion stabilizers for implants |
| 07/25/2001 | EP1118323A2 Method of reducing morbidity and the risk of mortality |
| 07/25/2001 | EP1117804A2 Chimaeric proteins between members of tgf-beta superfamily |
| 07/25/2001 | EP1117795A2 Tgf-beta superfamily mutant members, including morphogenic proteins |
| 07/25/2001 | EP1117787A2 Slgp protein and nucleic acid molecule and uses therefor |
| 07/25/2001 | EP1117784A2 Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity |
| 07/25/2001 | EP1117781A2 Human membrane channel proteins |
| 07/25/2001 | EP1117778A2 Methods and compositions for inducing differentiation and apoptosis in cells that overexpress the notch protein |
| 07/25/2001 | EP1117776A1 ENZYMATIC SYNTHESIS OF ssDNA |
| 07/25/2001 | EP1117765A2 Stem cells bearing an fgf receptor on the cell surface |
| 07/25/2001 | EP1117695A1 Biocompatible polymers, preparation method and compositions containing same |
| 07/25/2001 | EP1117692A1 Tie2 agonist antibodies |
| 07/25/2001 | EP1117689A1 Bone morphogenetic protein antagonists based on the mature protein |
| 07/25/2001 | EP1117681A1 Novel peptides |
| 07/25/2001 | EP1117680A2 Ncam binding compounds |
| 07/25/2001 | EP1117667A1 BENZOTHIENO[3,2-c]PYRIDINES AS ALPHA2 ANTAGONISTS |
| 07/25/2001 | EP1117660A1 Thrombin inhibitors |
| 07/25/2001 | EP1117658A1 1,3-benzodiazepines with integrin inhibitory activity for use in the treatment of inflammatory disorders |
| 07/25/2001 | EP1117657A1 Phenylalanine derivatives as alpha 4 integrin inhibitors |
| 07/25/2001 | EP1117651A1 New bis-benzimidazoles |
| 07/25/2001 | EP1117648A1 Tetrahydroquinoline derivatives having selective activity for retinoid x receptors |
| 07/25/2001 | EP1117644A1 Benzamide derivatives as thrombin inhibitors |
| 07/25/2001 | EP1117640A1 Heterocyclic 2-substituted ketoamides useful for treating hair loss in mammals |
| 07/25/2001 | EP1117633A1 Diaminocyclobutene-3,4-dione derivatives, their preparation and use |
| 07/25/2001 | EP1117628A1 2, 4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors |
| 07/25/2001 | EP1117444A2 Hydrogels and water soluble polymeric carriers for drug delivery |
| 07/25/2001 | EP1117443A1 Peptide-based carrier devices for stellate cells |
| 07/25/2001 | EP1117438A1 Tie2 antagonist antibodies |
| 07/25/2001 | EP1117428A2 Compositions and methods for inhibiting angiogenesis |
| 07/25/2001 | EP1117426A2 Akt compositions for enhancing survival of cells |
| 07/25/2001 | EP1117425A2 Methods for the treatment of non-thyroid disorders |
| 07/25/2001 | EP1117423A2 Immortalized human keratinocyte cell line |
| 07/25/2001 | EP1117419A1 Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions |
| 07/25/2001 | EP1117414A1 Reduction of oxidative stress factors |
| 07/25/2001 | EP1117409A2 Use of benzenesulfonyl(thio)ureas for the treatment of dysfunctions of the autonomous nervous system |
| 07/25/2001 | EP1117405A2 Composition and method for treating allergic diseases |
| 07/25/2001 | EP1117403A1 Mglur5 antagonists for the treatment of pain and anxiety |
| 07/25/2001 | EP1117398A2 A method for treating inflammatory diseases by administering a thrombin inhibitor |
| 07/25/2001 | EP1117397A1 Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity |
| 07/25/2001 | EP1117396A1 A method to increase the excretion of non-sterol endogenous hydrophobic substances by increasing excretion of fat via the faeces |
| 07/25/2001 | EP1117395A1 Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same |
| 07/25/2001 | EP1117394A1 Combination of carnitines and resveratrol for prevention or treatment of cerebral and ageing disorders |
| 07/25/2001 | EP1117392A1 Method for preventing or delaying catheter-based revascularization |
| 07/25/2001 | EP0889876B1 Meta-substituted phenylene sulphonamide derivatives |
| 07/25/2001 | EP0788362B1 Phosponocarboxylate compounds for treating abnormal calcium and phosphate metabolism |
| 07/25/2001 | EP0772610B9 Dihydrobenzofuranes |
| 07/25/2001 | EP0765322B1 Indole derivatives as prodrugs of 5-ht1-like receptor agonists |
| 07/25/2001 | EP0741709B1 Aromatic 2-amino-imidazole derivatives as alpha-2a adrenoceptor agonists |
| 07/25/2001 | EP0684944B1 Coupling product obtained from hystamine and an amino acid |
| 07/25/2001 | EP0577605B1 G protein-coupled glutamate receptors |
| 07/25/2001 | CN1305589A Improved immunodiagnostic assays using reducing agents |
| 07/25/2001 | CN1305525A Phagocytic assay method |
| 07/25/2001 | CN1305497A Monoclonal antibodies directed against the G3BP protein and use |
| 07/25/2001 | CN1305496A Cyclic somatostatin analogs |
| 07/25/2001 | CN1305494A Antithrombotic compounds |
| 07/25/2001 | CN1305493A Novel cyclosporins |
| 07/25/2001 | CN1305491A Crystalline forms of 1S-[1a(pha(2S, 3R), 9alpha]-6,10-dioxo-N-(2-ethoxy-5-oxo-tetrahydro-3-furanyl)-9-[[(1-isoquinolyl)carbonyl]-amino] actahydro-6H-piridazino [1,2-A][1,2] diazepin-1-carboxamide |
| 07/25/2001 | CN1305488A Testosterone derivative |
| 07/25/2001 | CN1305481A Piperazino derivatives as neurokinin antafonists |
| 07/25/2001 | CN1305478A Pyrazolopyrimidinone cGMP PDE 5 inhibitors for treatment of sexual dysfunction |
| 07/25/2001 | CN1305477A Azablicyclic 5-HT, receptor ligands |
| 07/25/2001 | CN1305473A N,N-disubstituded amide for inhibit binding of integrins to their receptors protein |
| 07/25/2001 | CN1305465A Aryl alkanoylpyridazines |
| 07/25/2001 | CN1305463A Substituted sulphonyl cyanamides, method for producing same and their use as medicament |
| 07/25/2001 | CN1305454A Anthranilic acid derivatives as inhibitors of CGMP phosphodiesterase |
| 07/25/2001 | CN1305383A Regulation of tyrosine bydroxylase |
| 07/25/2001 | CN1305382A Use of PEG-IFN-alpha and triazole nucleoside for treatment of chronic hepatitis C |
| 07/25/2001 | CN1305379A Method of treatment |
| 07/25/2001 | CN1305378A Therapeutic combinations of (selective) estrogen receptor modulators (SERM) and growth hormone secretagogues (GHS) for treating musculoskeletal fragility |
| 07/25/2001 | CN1305377A Methods for increasing levels of acetylcholine |
| 07/25/2001 | CN1305371A Multiparticulate pharmaceutical form with programmed and timed release and preparation method |
| 07/25/2001 | CN1305369A Pharmaceutical aerosol formulation |
| 07/25/2001 | CN1305343A Methods for increasing levels of acetylchotine |
| 07/25/2001 | CN1305342A Methods for reducing levels of homocysteine and C-reactive protein |
| 07/25/2001 | CN1304936A Quinoline-4-radical derivative II |
| 07/25/2001 | CN1304930A Arylsulfurylisooximino acid derivative |
| 07/25/2001 | CN1304754A Health-preserving capsule |
| 07/25/2001 | CN1304723A Tanshinone compounds containing dihydrofuran ring structure used for medicine to treat hepatic encephalopathy |
| 07/25/2001 | CN1304722A Medicinal composition for treating AIDS and its application |
| 07/25/2001 | CN1304721A Anti-AIDS medicine composition and its application |
| 07/25/2001 | CN1068879C Dihydrobenzofuranes |
| 07/25/2001 | CN1068784C External used medicinal liquor for preventing and curing multiple diseases |
| 07/25/2001 | CN1068778C Drag composition for treating and curing and its preparing method |
| 07/24/2001 | US6266622 Nuclear receptor ligands and ligand binding domains |
| 07/24/2001 | US6265588 Use as pharmaceuticals; as an antigen for production of antibodies and in diagnosis and purification |
| 07/24/2001 | US6265583 Cyclic sulfone containing retroviral protease inhibitors |